Strategic Priority 1:
Strengthening Pediatric Rare Disease Clinical Trial Capacity & ATP Readiness

Goal

To equip Canadian pediatric research institutions and affiliated hospitals to attract, develop, and conduct high-quality, innovative pediartic rare disease clinical trials, especially but not exclusively to Advanced Therapeutic Products; and to enhance readiness to administer ATPs within a research and clinical setting